Company launched TONMYA, approved by the FDA as a treatment for fibromyalgia, in November 2025In post hoc analysis of the pivotal RESILIENT ...
− Cardiovascular Magnetic Resonance (CMR) and Echocardiographic Analyses Demonstrate that Treatment with Vutrisiran Resulted in Significant Changes on Multiple Functional and Structural Cardiac ...
Amicus Therapeutics has released a post-hoc analysis from the PROPEL study, published in Muscle and Nerve, which evaluated the efficacy of cipaglucosidase alfa-atga combined with miglustat (cipa+mig) ...
SALT LAKE CITY, Oct. 30, 2025 – Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis of the Precision Medicine in ...
(RTTNews) - CalciMedica Inc. (CALC), a clinical-stage biopharmaceutical company, Tuesday said it presented new data based on a post-hoc analysis from the previously completed Phase 2 CARDEA study of ...
INCHEON, South Korea--(BUSINESS WIRE)--Celltrion today announced two-year results of subcutaneous infliximab (CT-P13 SC) dose escalation therapy at United European Gastroenterology (UEG) Week 2024 in ...
A post hoc analysis of the phase 3b JUMP trial supports the real-world use of ruxolitinib with anemia supportive care to maintain dosing and clinical outcomes in patients with myelofibrosis, offering ...
MILAN, Italy — The antisense oligonucleotide vupanorsen substantially reduces very low density lipoprotein (VLDL) and remnant cholesterol levels in patients with raised lipids despite statin therapy, ...
Recognizing that a patient’s kidney function can impact the efficacy of SGLT inhibitors, we conducted this post hoc analysis of clinical data from two identically-designed trials in patients with type ...
Respiratory sarcopenia, defined by low diaphragm thickness and reduced FVC, is associated with increased 2-year mortality in HF.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results